Aspira Women’s Health Strengthens Board of Directors with the Addition of Dr. Sandra E. Brooks

Rhea-AI Summary

Aspira Women’s Health, Inc. (Nasdaq: AWH) has appointed Dr. Sandra E. Brooks to its Board of Directors, enhancing its leadership team amid growth. With a strong background as a gynecologic oncologist and physician executive, Dr. Brooks brings valuable insights to the company as it aims to expand into larger healthcare systems and address gynecologic diseases. This change increases the Board's female representation to a majority, reflecting the company's commitment to diversity. Aspira focuses on innovative testing solutions to improve women's health, particularly in ovarian cancer risk assessment.

Positive

• Dr. Brooks' extensive experience in gynecologic oncology and healthcare systems may lead to better strategic direction.
• The Board now has a majority female representation, enhancing diversity and perspectives.

Negative

• Potential concerns about continuity in leadership experience could arise with the addition of a new Board member.

AUSTIN, Texas, Nov. 09, 2020 (GLOBE NEWSWIRE) -- Aspira Women’s Health, Inc. (Nasdaq: AWH), a bioanalytical-based women’s health company, today announced the appointment of Sandra E. Brooks, MD, MBA to its Board of Directors.  The addition of Dr. Brooks brings the Board composition to seven members with the majority now female. 

“It’s a tremendous honor to welcome Dr. Brooks to our Board of Directors at this important phase in the evolution of Aspira Women’s Health.  Dr. Brooks brings a wealth of knowledge and experience as a gynecologic oncologist by training as well as an experienced physician executive.  Her significant insights will be invaluable as we pursue larger healthcare systems and expand into other gynecologic diseases,” stated Valerie Palmieri, President, and CEO of Aspira Women’s Health. 

About Sandra E. Brooks, MD, MBA
Dr. Brooks is Senior Vice President & Chief Medical Officer at Thomas Jefferson University Hospitals, Center City Division, and a Professor in the Department of Obstetrics and Gynecology, Sidney Kimmel Medical College. Dr. Brooks trained in Obstetrics and Gynecology at the Hospital of the University of Pennsylvania and in Gynecologic Oncology at the Brigham and Women’s Hospital, Harvard Medical School, Dr. Brooks also served as Professor and Director of the Division of Gynecology Oncology at the University of Maryland for 10 years where in addition to clinical practice, and teaching trainees, her research focused on health services and cancer disparities. Dr. Brooks received her MBA in Medical Services Management at Johns Hopkins University before transitioning to physician executive roles in multi-site ambulatory and health system settings.

“It is my absolute pleasure to be a board member of a company focused on improving women’s lives, and has the potential to detect ovarian cancer risk in populations of women for whom established assays may less sensitive,” stated Dr. Sandra E. Brooks, Senior Vice President & Chief Medical Officer at Thomas Jefferson University Hospitals, Center City Division. “I believe my skills and perspective will complement the team, and look forward to serving with the other talented Board members.  

About Aspira Women’s Health Inc.
Aspira Women’s Health, Inc. (formerly known as, Vermillion inc., Nasdaq: VRML) is transforming women’s health with the discovery, development, and commercialization of innovative testing options and bio-analytical solutions that help physicians assess risk, optimize patient management and improve gynecologic health outcomes for women.  ASPIRA is particularly focused on closing the ethnic disparity gap in ovarian cancer risk assessment and developing solutions for pelvic diseases such as pelvic mass risk assessment and endometriosis. OVA1® plus includes our FDA-cleared products, OVA1^®, and OVERA^® to detect risk of ovarian malignancy in women with adnexal masses. ASPIRA GenetiX^TM testing offers both targeted and comprehensive genetic testing options with a gynecologic focus.  With over 10 years of expertise in ovarian cancer risk assessment, ASPIRA is delivering a portfolio of pelvic mass products over a patient’s lifetime with our cutting-edge research. The next generation of products in development are OVANEX^TM and EndoCheck^TM. Visit our website for more information at www.aspirawh.com.

Investor Relations Contact:
Ashley R. Robinson
LifeSci Advisors, LLC
Tel 617-430-7577
Arr@lifesciadvisors.com

Media Contact:
Jaime Abrusci
Rx Medical Dynamics
Tel 646-599-8606
jabrusci@rxmedyn.com

FAQ

Who is Dr. Sandra E. Brooks, and what is her role at Aspira?

Dr. Sandra E. Brooks has been appointed to the Board of Directors of Aspira Women’s Health, Inc., bringing her significant experience as a gynecologic oncologist and physician executive.

What impact may Dr. Brooks have on Aspira Women’s Health?

Dr. Brooks' expertise may help Aspira in expanding its reach within healthcare systems and enhancing its focus on gynecologic diseases.

When was Dr. Brooks appointed to the Board of Directors?

Dr. Brooks was appointed to the Board of Directors of Aspira Women’s Health on November 9, 2020.

What is the significance of having a majority female Board at Aspira?

Having a majority female Board at Aspira reflects the company’s commitment to diversity and may contribute to more comprehensive decision-making.

What does Aspira Women’s Health focus on?

Aspira Women’s Health focuses on innovative testing options and bio-analytical solutions aimed at improving gynecologic health outcomes, particularly in ovarian cancer risk assessment.